Israel -
hebraisk -
Ministry of Health
מאלוקס פלוס תרחיף
pharma shalom - aluminium hydroxide; magnesium hydroxide; simethicone - תרחיף - aluminium hydroxide 175 mg / 5 ml; magnesium hydroxide 200 mg / 5 ml; simethicone 25 mg / 5 ml
Israel -
hebraisk -
Ministry of Health
מאלוקס תרחיף
pharma shalom - aluminium hydroxide; magnesium hydroxide - תרחיף - aluminium hydroxide 175 mg / 5 ml; magnesium hydroxide 200 mg / 5 ml - ordinary salt combinations
Israel -
hebraisk -
Ministry of Health
סונגה נייט
pharma shalom - melissa officinalis; valerian dry extract - טבליות מצופות - valerian dry extract 120 mg; melissa officinalis 80 mg
Israel -
hebraisk -
Ministry of Health
ריכוך ציפורן חודרנית
כ.י.ד ערוץ הקניות בעמ - ריכוך ציפורן חודרנית
Israel -
hebraisk -
Ministry of Health
אימוראן טבליות 25 מג
padagis israel agencies ltd, israel - azathioprine - טבליות מצופות פילם - azathioprine 25 mg - azathioprine - azathioprine - immunosuppressive agent used in transplantation surgery for suppression of graft rejection. for special cases of rheumatoid arthritis- not responsive to other agents- and only by rheumatology experts in hospitals or rheumatic clinics.
Israel -
hebraisk -
Ministry of Health
אימוראן טבליות 50 מג
padagis israel agencies ltd, israel - azathioprine - טבליות מצופות פילם - azathioprine 50 mg - azathioprine - azathioprine - immunosupressive agent used in transplantation surgery for suppression of graft rejection. for special cases of rheumatoid artritis, not responsive to other agents, and only by rheumatology experts in hospitals or rheumatic clinics.
Israel -
hebraisk -
Ministry of Health
טייסברי
medison pharma ltd - natalizumab - תרכיז להכנת תמיסה לאינפוזיה - natalizumab 300 mg / 15 ml - natalizumab - natalizumab - tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis . to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. the safety and efficacy of tysabri beyond two years are unknown. because tysabri increases the risk of progressive multifocal leukoencephalopathy (pml), an opportunistic viral infection of the brain that usually leads to death or severe disability. tysabri is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate multiple sclerosis therapies. safety and efficacy in patients with chronic progressive multiple sclerosis have not been studied.